Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.

被引：1
|
作者：
Esfahani, Khashayar
Ferrario, Cristiano
Le, Philippe
Panasci, Lawrence C.
机构：
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e11585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11585
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+breast cancer.
    Kandagatla, Pridvi
    Decker, Joseph
    Wan, Lei
    Bernstein, Regan
    Shea, Lonnie
    Jeruss, Jacqueline Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Phase I trial of gemcitabine plus trastuzumab and pertuzumab in previously treated metastatic HER2+breast cancer.
    Soliman, Hatem Hussein
    Khambati, Fatema
    Han, Hyo S.
    Ismail-Khan, Roohi
    Loftus, Loretta S.
    Minton, Susan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [35] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [36] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [37] Breast MRI as a radiomic biomarker of immune enrichment in HER2+breast cancer.
    Kennedy, Laura
    Durenberger, Grace
    Stanton, Sasha E.
    Vinayak, Shaveta
    Dintzis, Suzanne
    Partridge, Savannah C.
    Gadi, Vijayakrishna K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Is the combination of trastuzumab and vinorelbine an active regimen in metastatic breast cancer patients overexpressing HER2/neu?
    Czerniawska, M
    Jagiello-Gruszfeld, AI
    Zbrzezniak, J
    Wachula, E
    Kazarnowicz, A
    Sikorska, M
    Szablowska-Siwik, S
    Ziomek, M
    Gugala, K
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 277 - 277
  • [39] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    [J]. Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [40] Trastuzumab and Vinorelbine combination in the treatment of metastatic breast cancer
    Bayo, J. L.
    Mayordomo, J. I.
    Rovira, P. Sanchez
    Gonzalez, E.
    Bueno, J. M. Garcia
    Ramos, M.
    Crespo, C.
    Illarramendi, J.
    Valerdi, J.
    Palomo, A. Garcia
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 130 - 130
12345